Evaluation of A Marketed Silicone Hydrogel Spherical Lens Used for Monovision Correction of Presb… (NCT04073186) | Clinical Trial Compass
CompletedNot Applicable
Evaluation of A Marketed Silicone Hydrogel Spherical Lens Used for Monovision Correction of Presbyopia
United States91 participantsStarted 2019-08-07
Plain-language summary
This is a single-masked, dispensing clinical trial. A total of approximately 48 myopic and 32 hyperopic eligible subjects will be targeted to complete the study. Subjects will be fit in the study lens, optimized if required and worn for approximately 2 weeks. Subjects will then have a washout period of approximately 1 week and be refit in the lenses and be dispensed for an additional 2 weeks of wear.
Who can participate
Age range40 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
✓. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
✓. The subject must be between 40 and 70 years of age at the time of screening.
✓. Subjects must own a wearable pair of spectacles if required for their distance vision.
✓. The subject must be an adapted monovision soft contact lens wearer in both eyes (i.e., worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month of more duration).
✓. The subject's distance spherical equivalent refraction must be in the range of +3.50 D to -4.00 D in each eye.
✓. The subject's refractive cylinder must be ≤1.00 D in each eye.
✓. The subject's ADD power must be in the range of +0.75 D to +2.50 D.
Exclusion criteria
✕. Currently Pregnant or lactating.
✕. Any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g., hepatitis, tuberculosis).
. Use of any of the following medications within 1 week prior to enrollment: oral retinoid isotretinoin (e.g. Accutane), oral tetracyclines, oral phenothiazines (e.g., Haldol, Mellaril, Thorazine, Elavil, Pamelor, Compazine), systemic steroids.
✕. Any previous, or planned, ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, lid procedures, cataract surgery, retinal surgery, dacryocystorhinostomy, etc.).
✕. Use of any ocular medication, with the exception of rewetting drops.
✕. Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.
✕. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
✕. Any known hypersensitivity or allergic reaction to OPTI-FREE® Puremoist® care cleaning solution, non-preserved rewetting drop solution or sodium fluorescein.